Press Releases
- Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
Feb 14, 2012, 8:35 AM EST - Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods to Target Abnormal Tau Protein in Treatment of Alzheimer's disease
Feb 7, 2012, 8:30 AM EST - Intellect Neurosciences Issues Letter to Shareholders
Feb 2, 2012, 1:44 PM EST - Intellect Neurosciences, Inc. to Present at BIO Asia International Conference
Jan 17, 2012, 9:35 AM EST - Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
Dec 15, 2011, 9:35 AM EST - Intellect Neurosciences, Inc. to Present at OneMedForum
Dec 14, 2011, 9:35 AM EST - Intellect Neurosciences Obtains Two New Patents in Japan for Its Alzheimer's Immunotherapy Programs
Nov 8, 2011, 9:35 AM EST - Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application
Nov 3, 2011, 9:35 AM EDT - Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimer's Disease and Other Proteinopathies
Oct 26, 2011, 9:35 AM EDT - Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
Oct 19, 2011, 10:00 AM EDT
